In its latest quarterly update, Inspire Medical Systems unveiled Project Horizon, a strategic initiative focused on operational streamlining, workforce reduction, and supply chain optimization to bolster revenue growth. The Company continues to capitalize on its FDA-approved hypoglossal nerve stimulation device for moderate to severe obstructive sleep apnea (OSA), supported by extensive clinical data and widespread reimbursement coverage. While revenue growth shows signs of deceleration against a backdrop of capacity constraints among ENT surgeons, Inspire's ongoing R&D investments and market access efforts position it well for geographic and indication expansion. Risk factors center on execution risks of the growth plan and regulatory or reimbursement uncertainties.